NEK7

Summary

NEK7 (NIMA related kinase 7, HGNC:13386) is a protein-coding gene on chromosome 1q31.3, encoding Serine/threonine-protein kinase Nek7 (Q8TDX7). Protein kinase which plays an important role in mitotic cell cycle progression.

NIMA-related kinases share high amino acid sequence identity with the gene product of the Aspergillus nidulans ’never in mitosis A’ gene, which controls initiation of mitosis.

Source: NCBI Gene 140609 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 31 total
• Druggable target: yes — 15 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_133494

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13386
Approved symbol	NEK7
Name	NIMA related kinase 7
Location	1q31.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000151414
Ensembl biotype	protein_coding
OMIM	606848
Entrez	140609

Gene structure

Transcript identifiers

Ensembl transcripts: 53 — 51 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000367383, ENST00000367385, ENST00000391974, ENST00000417895, ENST00000442588, ENST00000493790, ENST00000538004, ENST00000544035, ENST00000876078, ENST00000876079, ENST00000876080, ENST00000876081, ENST00000876082, ENST00000876083, ENST00000876084, ENST00000876085, ENST00000876086, ENST00000876087, ENST00000876088, ENST00000876089, ENST00000876090, ENST00000876091, ENST00000876092, ENST00000876093, ENST00000876094, ENST00000876095, ENST00000876096, ENST00000876097, ENST00000876098, ENST00000876099, ENST00000876100, ENST00000876101, ENST00000876102, ENST00000938615, ENST00000961624, ENST00000961625, ENST00000961626, ENST00000961627, ENST00000961628, ENST00000961629, ENST00000961630, ENST00000961631, ENST00000961632, ENST00000961633, ENST00000961634, ENST00000961635, ENST00000961636, ENST00000961637, ENST00000961638, ENST00000961639, ENST00000961640, ENST00000961641, ENST00000961642

RefSeq mRNA: 1 — MANE Select: NM_133494 NM_133494

CCDS: CCDS1394

Canonical transcript exons

ENST00000367385 — 10 exons

Exon	Start	End
ENSE00000999456	198264125	198264235
ENSE00000999457	198262575	198262637
ENSE00001067833	198277961	198278069
ENSE00001195921	198253040	198253180
ENSE00001444396	198319412	198322420
ENSE00001661619	198156998	198157276
ENSE00003478699	198297127	198297240
ENSE00003566226	198278954	198279061
ENSE00003583530	198292945	198293039
ENSE00003639938	198232553	198232637

Expression profiles

Bgee: expression breadth ubiquitous, 294 present calls, max score 99.38.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 60.0581 / max 709.1135, expressed in 1818 samples.

FANTOM5 promoters (14 alternative TSS)

Promoter ID	TPM avg	Samples expressed
7550	54.4762	1817
7551	3.4759	1253
7549	0.3701	138
7565	0.3564	157
7571	0.3126	127
7567	0.2162	66
7566	0.1755	62
7569	0.1425	36
7556	0.1208	48
7572	0.1165	26

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
heart right ventricle	UBERON:0002080	99.38	gold quality
myocardium	UBERON:0002349	98.96	gold quality
germinal epithelium of ovary	UBERON:0001304	98.88	gold quality
left ventricle myocardium	UBERON:0006566	98.74	gold quality
gluteal muscle	UBERON:0002000	98.59	gold quality
cardiac muscle of right atrium	UBERON:0003379	98.47	gold quality
superficial temporal artery	UBERON:0001614	98.12	gold quality
calcaneal tendon	UBERON:0003701	98.10	gold quality
mucosa of paranasal sinus	UBERON:0005030	98.06	gold quality
blood vessel layer	UBERON:0004797	97.99	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	97.93	gold quality
lower lobe of lung	UBERON:0008949	97.83	gold quality
amniotic fluid	UBERON:0000173	97.82	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	97.78	gold quality
vena cava	UBERON:0004087	97.72	gold quality
biceps brachii	UBERON:0001507	97.68	gold quality
corpus callosum	UBERON:0002336	97.48	gold quality
triceps brachii	UBERON:0001509	97.44	gold quality
medial globus pallidus	UBERON:0002477	97.38	gold quality
vastus lateralis	UBERON:0001379	97.36	gold quality
cauda epididymis	UBERON:0004360	97.36	gold quality
globus pallidus	UBERON:0001875	97.06	gold quality
jejunum	UBERON:0002115	97.05	gold quality
visceral pleura	UBERON:0002401	96.98	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	96.98	gold quality
subthalamic nucleus	UBERON:0001906	96.92	gold quality
jejunal mucosa	UBERON:0000399	96.91	gold quality
deltoid	UBERON:0001476	96.91	gold quality
bronchial epithelial cell	CL:0002328	96.86	gold quality
tendon	UBERON:0000043	96.84	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.87
E-MTAB-10290	no	261.66
E-MTAB-6058	no	241.98
E-MTAB-6379	no	216.50

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

214 targeting NEK7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-5692A	100.00	74.40	6850
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-371B-5P	99.99	75.34	4759

Literature-anchored findings (GeneRIF, showing 34)

• Activated by Nercc1/NEK9; part of the mitotic casscade. (PMID:12840024)
• a role for Nek7 in regulating proper spindle assembly and mitotic progression. (PMID:17101132)
• In consistent to the proposal, we observed a decrease in the centrosomal gamma-tubulin levels and reduction of the microtubule re-growth activity in the NEK7-suppressed cells. (PMID:17586473)
• both Nek6 and Nek7 are activated in mitosis and that interfering with their activity by either depletion or expression of reduced-activity mutants leads to mitotic arrest and apoptosis (PMID:19414596)
• The activity of Nek6 and Nek7, but not the tyrosine mutant, is increased by interaction with the Nek9 noncatalytic C-terminal domain, suggesting a mechanism in which the tyrosine is released from its autoinhibitory position. (PMID:19941817)
• Nek9 is a Plk1-activated kinase that controls early centrosome separation through Nek6/7 and Eg5. (PMID:21642957)
• NEK7 is essential for PCM accumulation in a cell cycle stage-specific manner. (PMID:22100915)
• Precise MT dynamic instability is critical for accurate shaping of the mitotic spindle and for cilium formation, and higher MT dynamicity is associated with tumorigenicity (PMID:23313050)
• Nek7, was significantly associated with certain clinicopathologic indices in gallbladder carcinoma (PMID:23359173)
• Studies indicate that autophosphorylation of Nek7 and Plk4 occurred through an intermolecular mechanism, the kinases Aurora-A and Chk2 followed an intramolecular mechanism. (PMID:23821772)
• Results show that NEK7 was directly regulated by WHSC1 through H3K36me2 and its knockdown significantly reduced cell-cycle progression, indicating that NEK7 is a key player in the molecular pathway regulated by WHSC1. (PMID:25280969)
• RGS2 or Nek7 depletion or even overexpression of wild-type or kinase-dead Nek7, reduced gamma-tubulin from the mitotic spindle poles. (PMID:25664600)
• Nek7 increased Ser/Thr phosphorylation of Anks3 primarily within ankyrin domain.Interaction with Anks3 led to cytoplasmic retention and nuclear exclusion of Nek7. (PMID:26188091)
• The C-terminal domain of Nek9 activates Nek7 through promoting back-to-back dimerization. (PMID:26522158)
• NEK7 serves as a cellular switch that enforces mutual exclusivity of the inflammasome response and cell division. (PMID:26642356)
• Study highlights for the first time the possible role of Nek7 in HCC progression. Nek7 would be a useful biomarker that early predicts HCC patients at higher risk of poor prognosis. (PMID:26921196)
• Studies indicate that NIMA related kinase 7 (NEK7) targets at NLRP3 protein and involves in the activation of NLRP3 inflammasome. (PMID:27563009)
• TRF1 phosphorylation by Nek7 favors the binding of shelterin protein TIN2 and disfavors E3 ligase Fbx4 interaction, thus preventing TRF1 ubiquitination and proteasome degradation to maintain telomere integrity. (PMID:28216227)
• Results demonstrate that NEK7 is involved in the timely regulation of G1 progression, S-phase entry, and procentriole formation. (PMID:28539406)
• Signaling cascade of the NIMA-related kinases (Neks) Nek6, Nek7, and Nek9 is required for the localization and function of two kinesins essential for cytokinesis, Mklp2 and Kif14 to properly coordinate cytokinesis. (PMID:28630147)
• The co-chaperone UNC45A is essential for the expression of mitotic kinase NEK7 and tumorigenesis. (PMID:30737284)
• Aurora A kinase expression was positively correlated with YAP in lung cancer. Aurora A depletion suppresses lung cancer cell colony formation, which could be reversed by YAP ectopic overexpression. (PMID:31160567)
• data suggest that NEK7 bridges adjacent NLRP3 subunits with bipartite interactions to mediate the activation of the NLRP3 inflammasome (PMID:31189953)
• Mitotic phosphorylation by NEK6 and NEK7 reduces the microtubule affinity of EML4 to promote chromosome congression. (PMID:31409757)
• Glutathione Transferase Omega-1 Regulates NLRP3 Inflammasome Activation through NEK7 Deglutathionylation. (PMID:31577945)
• NEK7 interacts with NLRP3 to modulate the pyroptosis in inflammatory bowel disease via NF-kappaB signaling. (PMID:31787755)
• EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7. (PMID:32184261)
• Nek7 conformational flexibility and inhibitor binding probed through protein engineering of the R-spine. (PMID:32242624)
• Micro-ribonucleic acid-23a-3p prevents the onset of type 2 diabetes mellitus by suppressing the activation of nucleotide-binding oligomerization-like receptor family pyrin domain containing 3 inflammatory bodies-caused pyroptosis through negatively regulating NIMA-related kinase 7. (PMID:32881354)
• Expression of the NEK7/NLRP3 inflammasome pathway in patients with diabetic lower extremity arterial disease. (PMID:33323459)
• Hsa-miR-372-5p regulates the NIMA related kinase 7 and IL-1beta release in NK/T-cell lymphoma. (PMID:34080953)
• The Inflammasome Activity of NLRP3 Is Independent of NEK7 in HEK293 Cells Co-Expressing ASC. (PMID:36142182)
• ZDHHC5-mediated NLRP3 palmitoylation promotes NLRP3-NEK7 interaction and inflammasome activation. (PMID:38092000)
• P2X7R Modulates NEK7-NLRP3 Interaction to Exacerbate Experimental Autoimmune Prostatitis via GSDMD-mediated Prostate Epithelial Cell Pyroptosis. (PMID:38993566)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	nek7	ENSDARG00000056966
mus_musculus	Nek7	ENSMUSG00000026393
rattus_norvegicus	Nek7	ENSRNOG00000000657
caenorhabditis_elegans		WBGENE00008956

Paralogs (8): NEK11 (ENSG00000114670), NEK2 (ENSG00000117650), NEK6 (ENSG00000119408), NEK9 (ENSG00000119638), NEK3 (ENSG00000136098), NEK8 (ENSG00000160602), NEK10 (ENSG00000163491), NEK5 (ENSG00000197168)

Protein

Protein identifiers

Serine/threonine-protein kinase Nek7 — Q8TDX7 (reviewed: Q8TDX7)

Alternative names: Never in mitosis A-related kinase 7

All UniProt accessions (4): C9J1H8, F5H3U7, F8WAG2, Q8TDX7

UniProt curated annotations — full annotation on UniProt →

Function. Protein kinase which plays an important role in mitotic cell cycle progression. Required for microtubule nucleation activity of the centrosome, robust mitotic spindle formation and cytokinesis. Phosphorylates EML4 at ‘Ser-146’, promoting its dissociation from microtubules during mitosis which is required for efficient chromosome congression. Phosphorylates RPS6KB1. Acts as an essential activator of the NLRP3 inflammasome assembly independently of its kinase activity. Acts by unlocking NLRP3 following NLRP3 tranlocation into the microtubule organizing center (MTOC), relieving NLRP3 autoinhibition and promoting formation of the NLRP3:PYCARD complex, and activation of CASP1. Serves as a cellular switch that enforces mutual exclusivity of the inflammasome response and cell division: interaction with NEK9 prevents interaction with NLRP3 and activation of the inflammasome during mitosis.

Subunit / interactions. Monomer. Interacts with NEK9; interaction takes place during mitosis; it relieves NEK7 autoinhibition and prevents interaction with NLRP3. Interacts with ANKS3; this interaction alters the subcellular distribution of NEK7 by preventing its nuclear translocation. Interacts (via N-terminus) with NLRP3 (via LRR repeat domain); the interaction is required for the formation of the complex NLRP3:PYCARD, oligomerization of PYCARD and activation of CASP1. (Microbial infection) Interacts with human cytomegalovirus protein US18; this interaction promotes inflammasome assembly.

Subcellular location. Nucleus. Cytoplasm. Cytoskeleton. Spindle pole. Microtubule organizing center. Centrosome.

Tissue specificity. Highly expressed in lung, muscle, testis, brain, heart, liver, leukocyte and spleen. Lower expression in ovary, prostate and kidney. No expression seen in small intestine.

Post-translational modifications. Phosphorylation at Ser-195 required for its activation.

Activity regulation. Binding to NEK9 stimulates its activity by releasing the autoinhibitory function of Tyr-97.

Domain organisation. Displays an autoinhibited conformation: Tyr-97 side chain points into the active site, interacts with the activation loop, and blocks the alphaC helix. The autoinhibitory conformation is released upon binding with NEK9. The NTE (N-terminal extension) motif is a structural component of the catalytic domain and thus contributes to activity.

Similarity. Belongs to the protein kinase superfamily. NEK Ser/Thr protein kinase family. NIMA subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8TDX7-1	1	yes
Q8TDX7-2	2

RefSeq proteins (1): NP_598001* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR001245	Ser-Thr/Tyr_kinase_cat_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site

Pfam: PF00069

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (70 total): mutagenesis site 29, helix 12, strand 10, turn 4, modified residue 3, splice variant 2, sequence variant 2, region of interest 2, binding site 2, chain 1, domain 1, active site 1, site 1

Structure

Experimental structures (PDB)

13 structures.

PDB	Method	Resolution (Å)
2WQM	X-RAY DIFFRACTION	2.1
8WS0	X-RAY DIFFRACTION	2.12
2WQN	X-RAY DIFFRACTION	2.3
8WS1	X-RAY DIFFRACTION	2.4
5DE2	X-RAY DIFFRACTION	2.78
9NFQ	X-RAY DIFFRACTION	3.25
6S75	X-RAY DIFFRACTION	3.3
6S76	X-RAY DIFFRACTION	3.38
8EJ4	ELECTRON MICROSCOPY	3.4
9H59	ELECTRON MICROSCOPY	3.4
6S73	X-RAY DIFFRACTION	3.5
6NPY	ELECTRON MICROSCOPY	3.8
8SXN	ELECTRON MICROSCOPY	4.04

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TDX7-F1	87.83	0.66

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 161 (proton acceptor); 97 (autoinhibitory)

Ligand- & substrate-binding residues (2): 40–48; 63

Post-translational modifications (3): 195, 1, 5

Mutagenesis-validated functional residues (29):

Position	Phenotype
28	significant decrease in catalytic activity; when associated with a-31.
31	significant decrease in catalytic activity; when associated with a-28.
33	significant decrease in catalytic activity.
90	reduced protein kinase activity.
90	strongly reduced protein kinase activity.
96	strongly increased protein kinase activity.
97	5-fold increase in catalytic activity.
97	moderate increase in catalytic activity.
122	decreased interaction with nek9 and subsequent activation of nek7 kinase activity.
125	does not affect interaction with nek9.
128	does not affect interaction with nlrp3.
129	decreased interaction with nlrp3.
130	does not affect interaction with nek9.
131	abolished interaction with nek9 and subsequent activation of nek7 kinase activity.
131	decreased interaction with nlrp3.
132	abolished interaction with nek9 and subsequent activation of nek7 kinase activity.
132	does not affect interaction with nek9.
136	decreased interaction with nlrp3.
155	strongly reduced protein kinase activity.
169	does not affect interaction with nek9.
172	does not affect interaction with nek9.
195	abolished phosphorylation with nek9 and protein kinase activity.
260–265	decreased interaction with nlrp3.
260–261	decreased interaction with nlrp3.
261	does not affect interaction with nek9.

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

ID	Pathway
R-HSA-2980767	Activation of NIMA Kinases NEK9, NEK6, NEK7
R-HSA-3301854	Nuclear Pore Complex (NPC) Disassembly
R-HSA-9648025	EML4 and NUDC in mitotic spindle formation
R-HSA-1640170	Cell Cycle
R-HSA-2980766	Nuclear Envelope Breakdown
R-HSA-68875	Mitotic Prophase
R-HSA-68877	Mitotic Prometaphase
R-HSA-68886	M Phase
R-HSA-69278	Cell Cycle, Mitotic

MSigDB gene sets: 340 (showing top): GOBP_CHROMOSOME_ORGANIZATION, MULLIGHAN_NPM1_SIGNATURE_3_UP, GOBP_REGULATION_OF_PHOSPHORYLATION, GOBP_INFLAMMATORY_RESPONSE, ATACCTC_MIR202, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, GOBP_RESPONSE_TO_POTASSIUM_ION, GOBP_TELOMERE_ORGANIZATION, GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_RESPONSE_TO_METAL_ION, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS

GO Biological Process (16): protein phosphorylation (GO:0006468), regulation of mitotic cell cycle (GO:0007346), positive regulation of telomere maintenance (GO:0032206), cellular response to potassium ion (GO:0035865), spindle assembly (GO:0051225), positive regulation of NLRP3 inflammasome complex assembly (GO:1900227), protein secretion (GO:0009306), positive regulation of interleukin-1 beta production (GO:0032731), positive regulation of interleukin-18 production (GO:0032741), regulation of chromosome organization (GO:0033044), interleukin-18-mediated signaling pathway (GO:0035655), NLRP3 inflammasome complex assembly (GO:0044546), positive regulation of inflammatory response (GO:0050729), protein maturation (GO:0051604), pyroptotic inflammatory response (GO:0070269), interleukin-1-mediated signaling pathway (GO:0070498)

GO Molecular Function (10): protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), metal ion binding (GO:0046872), protein serine kinase activity (GO:0106310), molecular function activator activity (GO:0140677), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (8): spindle pole (GO:0000922), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), centrosome (GO:0005813), microtubule organizing center (GO:0005815), microtubule (GO:0005874), cytoskeleton (GO:0005856)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Nuclear Envelope Breakdown	2
M Phase	2
Mitotic Prometaphase	1
Mitotic Prophase	1
Cell Cycle, Mitotic	1
Cell Cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
cytokine-mediated signaling pathway	2
inflammatory response	2
protein kinase activity	2
microtubule cytoskeleton	2
phosphorylation	1
protein modification process	1
mitotic cell cycle	1
regulation of cell cycle	1
telomere maintenance	1
regulation of telomere maintenance	1
positive regulation of DNA metabolic process	1
positive regulation of chromosome organization	1
response to potassium ion	1
cellular response to metal ion	1
spindle organization	1
chromosome segregation	1
membraneless organelle assembly	1
positive regulation of protein-containing complex assembly	1
NLRP3 inflammasome complex assembly	1
positive regulation of inflammasome-mediated signaling pathway	1
regulation of NLRP3 inflammasome complex assembly	1
protein transport	1
secretion by cell	1
establishment of protein localization to extracellular region	1
protein localization to extracellular region	1
interleukin-1 beta production	1
regulation of interleukin-1 beta production	1
positive regulation of interleukin-1 production	1
positive regulation of cytokine production	1
interleukin-18 production	1
regulation of interleukin-18 production	1
regulation of organelle organization	1
chromosome organization	1
cellular response to interleukin-18	1
canonical inflammasome complex assembly	1
positive regulation of defense response	1
positive regulation of response to external stimulus	1
regulation of inflammatory response	1
gene expression	1

Protein interactions and networks

STRING

1196 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NEK7	NLRP3	Q96P20	994
NEK7	NEK9	Q8TD19	950
NEK7	CASP1	P29466	940
NEK7	PYCARD	Q9ULZ3	798
NEK7	GSDMD	P57764	794
NEK7	ANKS3	Q6ZW76	768
NEK7	BICD2	Q8TD16	762
NEK7	RCC1L	Q96I51	715
NEK7	IL1B	P01584	690
NEK7	DENND1A	Q8TEH3	684
NEK7	IL18	Q14116	658
NEK7	CRB2	Q5IJ48	656
NEK7	DENND1B	Q6P3S1	650
NEK7	LHX9	Q9NQ69	642
NEK7	LHX2	P50458	635

IntAct

295 interactions, top by confidence:

A	B	Type	Score
NEK6	NEK9	psi-mi:“MI:0914”(association)	0.780
NEK8	ANKS6	psi-mi:“MI:0914”(association)	0.710
NLRP3	NEK7	psi-mi:“MI:0915”(physical association)	0.680
NEK7	DDIT4L	psi-mi:“MI:0915”(physical association)	0.560
NEK7		psi-mi:“MI:0915”(physical association)	0.560
DNASE1L1	NEK7	psi-mi:“MI:0915”(physical association)	0.560
FUT2	NEK7	psi-mi:“MI:0915”(physical association)	0.560
GJA5	NEK7	psi-mi:“MI:0915”(physical association)	0.560
GNAO1	NEK7	psi-mi:“MI:0915”(physical association)	0.560
HLA-DRB3	NEK7	psi-mi:“MI:0915”(physical association)	0.560
HSD3B1	NEK7	psi-mi:“MI:0915”(physical association)	0.560
IDH1	NEK7	psi-mi:“MI:0915”(physical association)	0.560
KLRC1	NEK7	psi-mi:“MI:0915”(physical association)	0.560
LGALS1	NEK7	psi-mi:“MI:0915”(physical association)	0.560
LGALS8	NEK7	psi-mi:“MI:0915”(physical association)	0.560
EPCAM	NEK7	psi-mi:“MI:0915”(physical association)	0.560
MAGEA2	NEK7	psi-mi:“MI:0915”(physical association)	0.560
CNOT3	NEK7	psi-mi:“MI:0915”(physical association)	0.560
PPEF1	NEK7	psi-mi:“MI:0915”(physical association)	0.560
PSMC4	NEK7	psi-mi:“MI:0915”(physical association)	0.560
PSMD2	NEK7	psi-mi:“MI:0915”(physical association)	0.560
RAP1B	NEK7	psi-mi:“MI:0915”(physical association)	0.560
	NEK7	psi-mi:“MI:0915”(physical association)	0.560
TAFAZZIN	NEK7	psi-mi:“MI:0915”(physical association)	0.560
TCOF1	NEK7	psi-mi:“MI:0915”(physical association)	0.560
TDO2	NEK7	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (211): NEK7 (Affinity Capture-MS), NEK7 (Affinity Capture-MS), NEK7 (Affinity Capture-MS), NEK7 (Affinity Capture-MS), NEK7 (Affinity Capture-MS), NEK7 (Affinity Capture-MS), NEK7 (Affinity Capture-MS), NEK7 (Affinity Capture-MS), NEK7 (Affinity Capture-MS), NEK7 (Affinity Capture-MS), NEK7 (Affinity Capture-MS), NEK7 (Affinity Capture-MS), NEK7 (Affinity Capture-MS), NEK7 (Affinity Capture-MS), NEK7 (Affinity Capture-MS)

ESM2 similar proteins: A0A5B9GBF0, A1CPG7, A1D2C9, A1IVT7, A2BD05, A2QRF6, B0XR80, D3ZBE5, G1XJZ4, G5EDF7, G5EFM9, M1T7M3, O09110, O75716, O88697, P0CP69, P21708, P26696, P27361, P28482, P45985, P46196, P46734, P47809, P52564, P57760, P59895, P70236, Q0D0P5, Q0U4L8, Q1DUU8, Q1KTF2, Q2WFL5, Q4PC06, Q4W6D3, Q4WSF6, Q52PH6, Q56R42, Q5E9X2, Q63844

Diamond homologs: A0A078CGE6, A2BD05, A2QHV0, A2ZMH2, A7SNN5, D3ZBE5, D3ZGQ5, E9Q3S4, G5EFM9, H2L099, O01775, O13839, O14047, O22040, O22042, O35942, O61122, P11837, P22209, P41892, P48479, P48963, P51954, P51955, P51956, P51957, P59895, P84199, Q03428, Q08942, Q0CL79, Q0KHQ5, Q0WPH8, Q10GB1, Q2QAV0, Q2QMH1, Q3SWY6, Q3UGM2, Q40541, Q4FZD7

SIGNOR signaling

12 interactions.

A	Effect	B	Mechanism
NEK9	“up-regulates activity”	NEK7	phosphorylation
NEK7	“up-regulates activity”	KIF14	phosphorylation
NEK7	“up-regulates quantity by stabilization”	TERF1	phosphorylation
NEK7	“up-regulates activity”	TERF1	phosphorylation
NEK7	“up-regulates quantity”	TERF1	phosphorylation
NEK7	“down-regulates activity”	EML4	phosphorylation
NEK7	“up-regulates activity”	KIF11	phosphorylation
NEK7	“up-regulates activity”	EML4	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 112 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Intraflagellar transport	5	15.4×	2e-03
EML4 and NUDC in mitotic spindle formation	7	10.0×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

31 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	22
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3361 predictions. Top by Δscore:

Variant	Effect	Δscore
1:198232543:A:AG	acceptor_gain	1.0000
1:198232544:T:G	acceptor_gain	1.0000
1:198232548:TGCA:T	acceptor_loss	1.0000
1:198232550:CA:C	acceptor_loss	1.0000
1:198232550:CAG:C	acceptor_gain	1.0000
1:198232551:A:AG	acceptor_gain	1.0000
1:198232551:AGA:A	acceptor_gain	1.0000
1:198232552:G:C	acceptor_gain	1.0000
1:198232552:G:GG	acceptor_gain	1.0000
1:198232552:GA:G	acceptor_gain	1.0000
1:198232552:GAGTT:G	acceptor_gain	1.0000
1:198232633:CACAG:C	donor_loss	1.0000
1:198232634:ACAG:A	donor_loss	1.0000
1:198232636:AG:A	donor_loss	1.0000
1:198232637:GGTA:G	donor_loss	1.0000
1:198232638:G:C	donor_loss	1.0000
1:198232639:T:G	donor_loss	1.0000
1:198262569:TTTTA:T	acceptor_loss	1.0000
1:198262570:TTTA:T	acceptor_loss	1.0000
1:198262571:TTA:T	acceptor_loss	1.0000
1:198262572:TAG:T	acceptor_loss	1.0000
1:198262573:AG:A	acceptor_loss	1.0000
1:198262633:TTAAG:T	donor_loss	1.0000
1:198262634:TAAG:T	donor_loss	1.0000
1:198262635:AAG:A	donor_loss	1.0000
1:198262636:AG:A	donor_loss	1.0000
1:198262637:GG:G	donor_loss	1.0000
1:198262638:GTA:G	donor_loss	1.0000
1:198262639:T:A	donor_loss	1.0000
1:198264120:CTCAG:C	acceptor_loss	1.0000

AlphaMissense

1993 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:198253110:G:A	G43E	1.000
1:198253115:T:C	F45L	1.000
1:198253117:T:A	F45L	1.000
1:198253117:T:G	F45L	1.000
1:198253164:C:A	A61D	1.000
1:198253171:A:C	K63N	1.000
1:198253171:A:T	K63N	1.000
1:198262630:T:C	L85P	1.000
1:198264147:T:A	I95K	1.000
1:198264189:T:A	I109K	1.000
1:198278067:G:C	R160T	1.000
1:198278067:G:T	R160I	1.000
1:198278069:G:C	D161H	1.000
1:198278954:A:C	D161A	1.000
1:198278954:A:T	D161V	1.000
1:198278955:T:A	D161E	1.000
1:198278955:T:G	D161E	1.000
1:198278961:A:C	K163N	1.000
1:198278961:A:T	K163N	1.000
1:198278970:T:A	N166K	1.000
1:198278970:T:G	N166K	1.000
1:198279005:G:A	G178E	1.000
1:198279007:G:C	D179H	1.000
1:198279008:A:C	D179A	1.000
1:198279008:A:G	D179G	1.000
1:198279008:A:T	D179V	1.000
1:198279009:T:A	D179E	1.000
1:198279009:T:G	D179E	1.000
1:198279019:G:C	G183R	1.000
1:198292947:G:C	G198R	1.000

dbSNP variants (sampled 300 via entrez): RS1000048717 (1:198193781 T>C), RS1000066240 (1:198320697 G>C), RS1000076519 (1:198288770 C>T), RS1000090231 (1:198190505 T>C), RS1000120437 (1:198240513 A>G), RS1000124945 (1:198197104 C>T), RS1000133254 (1:198271387 A>G), RS1000155668 (1:198285097 C>A), RS1000164222 (1:198221189 A>G), RS1000166433 (1:198240151 A>G), RS1000204476 (1:198155647 C>T), RS1000216007 (1:198221500 A>C,G), RS1000222384 (1:198257648 A>G), RS1000225437 (1:198157604 G>A,C), RS1000236857 (1:198164981 C>T)

Disease associations

OMIM: gene MIM:606848 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST006054_3	High altitude adaptation	5.000000e-08
GCST008163_415	Height	2.000000e-06
GCST90000047_19	Age at first sexual intercourse	4.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0009105	high altitude adaptation
EFO:0009749	age at first sexual intercourse measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL4524130 (PROTEIN FAMILY), CHEMBL4849 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

15 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 123,452 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1789941	RUXOLITINIB	4	11,547
CHEMBL535	SUNITINIB	4	79,020
CHEMBL601719	CRIZOTINIB	4	14,403
CHEMBL522892	DOVITINIB	3	4,944
CHEMBL603469	LESTAURTINIB	3
CHEMBL1721885	SU-014813	2	363
CHEMBL475251	R-406	2	762
CHEMBL513909	BI-2536	2	895
CHEMBL572878	TOZASERTIB	2	2,998
CHEMBL5750400	OFIRNOFLAST	2	17
CHEMBL575448	BMS-754807	2	406
CHEMBL12089	BERBERINE CHLORIDE	1	1,860
CHEMBL1908397	KW-2449	1	622
CHEMBL494089	GSK-690693	1	2,061

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — NIMA (never in mitosis gene a)- related kinase (NEK) family

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
ofirnoflast	Inhibition	6.82	pIC50

Binding affinities (BindingDB)

4 measured of 4 human assays (4 total across all organisms); most potent 4 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Staurosporine	KD	1.7 nM
(3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazino)-1,3-dihydrobenzimidazol-2-ylidene]carbostyril	KD	520 nM
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM

ChEMBL bioactivities

59 potent at pChembl≥5 of 61 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.52	Kd	3	nM	K-252A
7.96	Kd	11	nM	R-406
6.81	Kd	156.4	nM	CHEMBL5653589
6.80	Kd	160	nM	FEDRATINIB
6.69	ED50	202.9	nM	CHEMBL5653589
6.68	Kd	210	nM	KW-2449
6.65	IC50	225	nM	CHEMBL5768122
6.65	IC50	225	nM	OFIRNOFLAST
6.65	IC50	225	nM	CHEMBL5887510
6.65	IC50	225	nM	CHEMBL5904011
6.65	IC50	225	nM	CHEMBL6001931
6.65	IC50	225	nM	CHEMBL5937522
6.65	IC50	225	nM	CHEMBL5870995
6.65	IC50	225	nM	CHEMBL5920415
6.45	Kd	354.5	nM	CHEMBL3752910
6.40	IC50	400	nM	CHEMBL5884752
6.40	IC50	400	nM	CHEMBL5862768
6.40	IC50	400	nM	CHEMBL5838706
6.40	IC50	400	nM	CHEMBL6015254
6.40	IC50	400	nM	CHEMBL5942727
6.40	IC50	400	nM	CHEMBL5907872
6.40	IC50	400	nM	CHEMBL5867153
6.40	IC50	400	nM	CHEMBL5750911
6.40	IC50	400	nM	CHEMBL5889029
6.40	IC50	400	nM	CHEMBL5954683
6.34	ED50	459.9	nM	CHEMBL3752910
6.19	Kd	650	nM	BMS-754807
6.00	IC50	1000	nM	CHEMBL5925841
6.00	IC50	1000	nM	CHEMBL6034961
6.00	IC50	1000	nM	CHEMBL5938770
6.00	IC50	1000	nM	CHEMBL5798421
6.00	IC50	1000	nM	CHEMBL5802111
6.00	IC50	1000	nM	CHEMBL5789057
6.00	IC50	1000	nM	CHEMBL6029291
6.00	IC50	1000	nM	CHEMBL5975783
6.00	IC50	1000	nM	CHEMBL5880303
5.67	Kd	2126	nM	GSK-690693
5.64	Kd	2300	nM	TAE-684
5.50	Kd	3200	nM	SU-014813
5.40	Kd	4000	nM	LESTAURTINIB
5.39	Kd	4100	nM	SUNITINIB
5.38	IC50	4200	nM	BERBERINE CHLORIDE
5.35	Kd	4500	nM	STAUROSPORINE
5.31	Kd	4900	nM	RUXOLITINIB
5.25	Kd	5600	nM	DOVITINIB
5.24	Kd	5700	nM	CRIZOTINIB
5.21	Kd	6100	nM	BI-2536
5.16	Kd	6900	nM	CHEMBL2425628
5.14	IC50	7280	nM	CHEMBL235641
5.06	Kd	8700	nM	TOZASERTIB

PubChem BioAssay actives

30 with measured affinity, of 983 total; 21 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
methyl (15S,16R,18R)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16-carboxylate	1425088: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0030	uM
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	1948828: Inhibition of NEK7 (unknown origin) assessed as dissociation constant	kd	0.0110	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148863: Binding affinity to human NEK7 incubated for 45 mins by Kinobead based pull down assay	kd	0.1564	uM
Fedratinib	1948828: Inhibition of NEK7 (unknown origin) assessed as dissociation constant	kd	0.1600	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	1948828: Inhibition of NEK7 (unknown origin) assessed as dissociation constant	kd	0.2100	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148863: Binding affinity to human NEK7 incubated for 45 mins by Kinobead based pull down assay	kd	0.3545	uM
(2S)-1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methylpyrrolidine-2-carboxamide	2167406: Binding affinity to NEK7 (unknown origin) by phage based competition assay	kd	0.6500	uM
4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(3S)-piperidin-3-yl]methoxy]imidazo[4,5-c]pyridin-4-yl]-2-methylbut-3-yn-2-ol	1425088: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	2.1260	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	624754: Binding constant for NEK7 kinase domain	kd	2.3000	uM
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	435666: Binding constant for full-length NEK7	kd	3.2000	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	507647: Binding affinity to NEK7	kd	4.0000	uM
Sunitinib	435666: Binding constant for full-length NEK7	kd	4.1000	uM
Berberine Chloride	1744523: Inhibition of purified recombinant human NEK7 incubated for 15 mins before ATP and substrate addition and further incubated for 40 mins by ADPGlo kinase assay	ic50	4.2000	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	435666: Binding constant for full-length NEK7	kd	4.5000	uM
Ruxolitinib	624754: Binding constant for NEK7 kinase domain	kd	4.9000	uM
4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one	435666: Binding constant for full-length NEK7	kd	5.6000	uM
Crizotinib	624754: Binding constant for NEK7 kinase domain	kd	5.7000	uM
4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide	624754: Binding constant for NEK7 kinase domain	kd	6.1000	uM
(4-hydroxypiperidin-1-yl)-[4-[[4-[4-(3-methylsulfonylpropoxy)indol-1-yl]pyrimidin-2-yl]amino]cyclohexyl]methanone	769502: Binding affinity to NEK7 (unknown origin)	kd	6.9000	uM
(8Z)-8-(1H-imidazol-5-ylmethylidene)-6H-pyrrolo[2,3-g][1,3]benzothiazol-7-one	1531804: Inhibition of human NEK7 using casein as substrate by [gamma-33P]-ATP assay	ic50	7.2800	uM
N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide	624754: Binding constant for NEK7 kinase domain	kd	8.7000	uM

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression	2
perfluorooctane sulfonic acid	decreases expression	2
Benzo(a)pyrene	affects methylation, increases methylation, increases mutagenesis	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
dicrotophos	decreases expression	1
2,4,6-tribromophenol	decreases expression	1
triphenyl phosphate	affects expression	1
arsenite	decreases reaction, affects binding	1
cobaltous chloride	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
Arsenic Trioxide	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Air Pollutants, Occupational	decreases expression	1
Cadmium	increases expression, increases abundance	1
Cisplatin	affects cotreatment, decreases expression	1
Dimethyl Sulfoxide	affects expression	1
Nickel	decreases expression	1
Silicon Dioxide	increases expression	1
Tamoxifen	decreases expression, affects expression, affects reaction	1
Thiram	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Urethane	increases expression	1
Valproic Acid	decreases methylation	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Aflatoxin B1	decreases methylation	1
Cadmium Chloride	increases expression, increases abundance	1

ChEMBL screening assays

275 unique, capped per target: 275 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4887137	Binding	NEK Invitrogen kinase activity assay	Data for DCP probe PF-04554878

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D8R6	Ubigene HCT 116 NEK7 KO	Cancer cell line	Male
CVCL_E0IW	Ubigene HeLa NEK7 KO	Cancer cell line	Female
CVCL_TA42	HAP1 NEK7 (-) 1	Cancer cell line	Male
CVCL_TA43	HAP1 NEK7 (-) 2	Cancer cell line	Male
CVCL_TA44	HAP1 NEK7 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.